BioNxt Solutions Inc. (CVE:BNXT)

PRESS RELEASE

published on 08/04/2026 at 09:05, 3 months 1 day ago

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
BioNxt Solutions Inc. provides update on proprietary drug delivery pipeline focusing on Cladribine for MS, autoimmune diseases, Everolimus, Semaglutide. Strengthening IP portfolio

BioNxt Solutions Inc. Intellectual Property Autoimmune Diseases Cladribine Drug Delivery Pipeline
BRIEF

published on 08/01/2026 at 00:30, 3 months 5 days ago

BioNxt Solutions émet de nouvelles options d'achat d'actions

Acquisition Options D'achat D'actions Solutions BioNxt Plan D'options Bourse Canadienne Des Valeurs Mobilières
BRIEF

published on 08/01/2026 at 00:30, 3 months 5 days ago

BioNxt Solutions Issues New Stock Options

Stock Options Canadian Securities Exchange Vesting BioNxt Solutions Option Plan
PRESS RELEASE

published on 08/01/2026 at 00:25, 3 months 5 days ago

BioNxt Solutions Announces Option Grants
BioNxt Solutions Inc. announces stock options grants under Option Plan to insiders, consultants, and employees. Focus on drug delivery innovations and cancer treatment platforms

Stock Options Cancer Treatment Innovations BioNxt Solutions Inc. Drug Delivery
BRIEF

published on 07/06/2026 at 09:10, 3 months 30 days ago

BioNxt Progresses with Sublingual Semaglutide ODF Development

Drug Delivery Pharmaceutical Development BioNxt Solutions Sublingual ODF GLP-1 Therapeutics
BRIEF

published on 07/06/2026 at 09:10, 3 months 30 days ago

BioNxt progresse dans le développement de l'ODF sublinguale de sémaglutide.

Développement Pharmaceutique Solutions BioNxt Administration De Médicaments ODF Sublingual Thérapeutiques GLP-1
PRESS RELEASE

published on 07/06/2026 at 09:05, 3 months 30 days ago

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
BioNxt Solutions Inc. announces progress in Semaglutide oral dissolvable film program for GLP-1 therapies, expanding into a rapidly growing pharmaceutical market

BioNxt Solutions Inc. Pharmaceutical Market Oral Dissolvable Film GLP-1 Therapies Semaglutide
BRIEF

published on 06/23/2026 at 23:25, 4 months 12 days ago

BioNxt Solutions Completes $2M Non-brokered Private Placement

Private Placement Securities Warrants Investments BioNxt Solutions
BRIEF

published on 06/23/2026 at 23:25, 4 months 12 days ago

BioNxt Solutions finalise un placement privé sans intermédiaire de 2 millions de dollars

Placement Privé Investissements Titres Mandats Solutions BioNxt
PRESS RELEASE

published on 06/23/2026 at 23:20, 4 months 12 days ago

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
BioNxt Solutions Inc. closes non-brokered private placement of units, plans to use proceeds for research and operations in Europe. Company updates on unsecured convertible debentures extension

Private Placement BioNxt Solutions Inc. Debt Extension European Research Bioscience Innovator

Published on 11/06/2026 at 05:15, 2 hours 17 minutes ago

Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 01:20, 6 hours 12 minutes ago

Presentation to Munich Mining Conference
Published on 11/06/2026 at 00:53, 6 hours 39 minutes ago

Sekur Private Data Engages Darkstar Capital for Investor Awareness and Sekur Product Distribution
Published on 11/06/2026 at 00:45, 6 hours 47 minutes ago

Gabriel Announces Closure of ICSID Annulment Proceedings
Published on 11/05/2026 at 23:55, 7 hours 37 minutes ago

Santé Canada autorise deux vaccins à ARNm de Moderna : un vaccin contre la grippe et un vaccin combiné contre la grippe et la COVID-19

View all ACCESSWIRE

Published on 11/06/2026 at 07:00, 31 minutes ago

ARYZTA announces upcoming departure of its CFO
Published on 11/06/2026 at 06:58, 34 minutes ago

Aperam - Third quarter 2026 results: “Transformation drives the best third quarter performance in four years”
Published on 11/06/2026 at 06:58, 34 minutes ago

Aperam - Third quarter 2026 results: “Transformation drives the best third quarter performance in four years”
Published on 11/06/2026 at 06:45, 47 minutes ago

Krones reports moderate growth and improved profitability in a challenging market environment
Published on 11/06/2026 at 06:30, 1 hour 1 minute ago

Share buyback program completed

View all EQS

Published on 11/05/2026 at 18:21, 13 hours 10 minutes ago

Capital et droits de vote au 31 octobre 2026
Published on 11/05/2026 at 18:21, 13 hours 10 minutes ago

Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 18:01, 13 hours 30 minutes ago

LNA SANTE : Chiffre d'Affaires T3 2026
Published on 11/05/2026 at 17:50, 13 hours 41 minutes ago

NRJ GROUP - Financial information Q3 2026
Published on 11/05/2026 at 17:50, 13 hours 41 minutes ago

NRJ GROUP - Information financière T3 2026

View all LES ECHOS COMFI WIRE

News